Topic: triple-negative breast cancer
Researchers have discovered seven gene alterations that could improve surveillance for triple-negative breast cancer risk.
Arcus Biosciences and Infinity Pharmaceuticals plan to mix their lead programs in triple-combination immunotherapy trials in breast and ovarian cancer.
A modified form of poliovirus seems to shrink breast tumors by latching onto a protein that's heavily expressed on the surface of some cancer cells.
Scientists have developed a small molecule that can selectively target RNA and could pave the way for a pill that can treat genetic diseases.
The latest update from Nektar and Bristol-Myers' immuno-oncology combo showed a drop in response rate for three cancers.
Merck and OncoSec partnered on a second immunotherapy combination, now in triple-negative breast cancer, following a melanoma study last year.
The funding will see Quentis' lead immunotherapy candidate into the clinic in 2019.
After disappointing data in leukemia, France’s Erytech is refocusing its red blood cell-encapsulated drug therapy to solid tumors.
A stem cell pathway could be targeted to create more effective treatments for triple-negative breast cancer.
Bicycle Therapeutics has returned to its big name backers for £40 million to fund the advance of cancer candidates into the clinic.